Life Sciences

Clinicians, biopharmas and researchers rely on our technology and evidence to extract new insights from multi-modality images.
Quibim is exhibiting at ASCO 2023

Case Studies

An increasing number of biopharma companies are looking for an imaging strategy. Combined with AI techniques, imaging can predict which patients will respond to a drug, finding the right candidates for clinical studies, detect patients at risk, and accelerate drug development programs


  • Oncology

    Our tissue-agnostic AI methods are applied at each stage of drug development programs. First we apply our AI techniques to harmonize image quality across hospitals and scanner models, then we perform automated organ and lesion detection. A tissue characterization follows to extract a signature based on the most relevant radiomics-based and deep features. These features are then used to develop predictive models of tumor growth, treatment response, overall survival, disease free survival, among many other patient outcomes.

  • Immunology

    Our AI-based tools provide patients with an early diagnosis for rheumatic diseases in the main imaging modalities. We support the digital transformation of therapy indication either during drug-development phases or in post-approval scenarios, deploying an integrated offering to healthcare providers.


  • Neuroscience

    We apply our AI-based methods for automated segmentation and quantification of brain tissues and abnormal lesions. We assess differences in the volume of brain regions in neurodegenerative and inflammatory diseases and in metabolic disorders, extracting surrogate imaging biomarkers.


  • Hematology

    We provide automated segmentation methods for lesions and organs in whole body PET/CT examinations. The most frequent clinical scenarios are lymphoma and multiple myeloma, extracting lesion-level features, which, combined at the patient level, can help in predicting treatment response in standard or advanced therapies as well as other phenomena like cytokine release syndrome (CRS) in cell therapies such as Chimeric Antigen Receptor T-cell therapies (CAR-T).

Do you want to be updated with our news?

By pressing submit you accept all the privacy policy and the terms and conditions of the Quibim website.

This field is for validation purposes and should be left unchanged.